Autolus Therapeutics plc
AUTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.10 | -0.01 | 0.08 |
| FCF Yield | -12.07% | -13.19% | -20.32% | -9.88% |
| EV / EBITDA | -6.39 | -9.62 | -11.31 | -6.11 |
| Quality | ||||
| ROIC | -12.27% | -9.33% | -9.56% | -33.30% |
| Gross Margin | -35.15% | -16.83% | -99.86% | -476,810.34% |
| Cash Conversion Ratio | 0.86 | 1.52 | 1.08 | 1.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 109.97% | 58.72% | 6.38% | 17.78% |
| Free Cash Flow Growth | 34.57% | 4.47% | -35.63% | 28.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 1.04 | -3.88 | 2.37 |
| Interest Coverage | -6.81 | 0.00 | -6.43 | 7.83 |
| Efficiency | ||||
| Inventory Turnover | 1.03 | 1.02 | 1.23 | 33.42 |
| Cash Conversion Cycle | 440.60 | 406.30 | 194.55 | 149,711.76 |